Research progress on soluble anti-Secretogranin Ⅲ in fundus neovascularization
10.3980/j.issn.1672-5123.2020.5.18
- VernacularTitle:分泌粒蛋白Ⅲ抗体治疗眼底新生血管的研究进展
- Author:
Bin-Bin Yang
1
Author Information
1. 1Guilin Medical College, Guilin 541000, Guangxi Zhuang Autonomous Region, China; 2Department of Ophthalmology, Affiliated Hospital of Guilin Medical College, Guilin 541000, Guangxi Zhuang Autonomous Region, China
- Publication Type:Review
- Keywords:
Secretogranin III;
vascular endothelial growth factor;
retinal neovascularization;
choroidal neovascularization
- From:
International Eye Science
2020;20(5):827-830
- CountryChina
- Language:Chinese
-
Abstract:
Scretogranin III(Scretogranin III, Scg3/SgIII)is a newly discovered angiogenic factor. Related studies in vivo and in vitro have confirmed that Scg3 plays an important role in the formation of fundus neovascularization. In recent years, some progress has been made in the treatment of fundus neovascularization with Scg3 antibody. It's mechanism of action is different from Vascular endothelial growth factor(VEGF). Scg3 is only expressed in pathological neovascularization, but in normal blood vessels, never be expressed, it is a newly discovered angiogenic factor with high selectivity. This paper summarizes the latest progress about its molecular structure of Scg3, signal transduction pathways and their applications in retinal neovascularization, the aim is to provide a new treatment idea for retinal neovascularization and choroidal neovascularization.
- Full text:202005018.pdf
